Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis.
Fiche publication
Date publication
avril 2022
Journal
Radiation oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CLAVIER Jean-Baptiste, Dr GUIHARD Sébastien
Tous les auteurs :
Issoufaly I, Petit C, Guihard S, Eugène R, Jung L, Clavier JB, Servagi Vernat S, Bellefqih S, Verret B, Bonnet N, Deutsch É, Rivera S
Lien Pubmed
Résumé
Moderately hypofractionated whole-breast radiotherapy (HFRT) has proven to be as safe and efficient as normofractionated radiotherapy (NFRT) in randomized trials resulting in major changes in clinical practice. Toxicity rates observed in selected clinical trial patients may differ from those observed in unselected patients with possible comorbidities and frailty in real-life. This study aimed to examine the influence of HFRT versus NFRT on acute toxicity and identify risks factors of dermatitis in real-life patients.
Mots clés
Acute toxicity, Breast cancer, Data-farming, Hypofractionation, Radiotherapy, Real-life data
Référence
Radiat Oncol. 2022 Apr 20;17(1):80